Skip to main content
SpringerLink
Log in

Development of Novel Solid Nanostructured Lipid Carriers for Bioavailability Enhancement Using a Quality by Design Approach

  • Research Article
  • Advancements in Modified-release Oral Drug Delivery - Delivery throughout the Gastro-intestinal Tract
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

α, β-Arteether (ART) antimalarial drug is used to treat chloroquine-resistant malaria and cerebral malaria. The drug’s solubility in water is relatively low (17 μg/mL), and 40% of the drug degrades in the stomach, resulting in poor bioavailability. This article discusses the quality by design technique used for formulation development and optimization of nanostructured lipid carriers (NLCs). The ART-NLCs were made by solvent diffusion method. To develop solid NLCs, the NLCs were freeze-dried and encapsulated in enteric-coated capsule shells. The prepared NLCs showed particle size ranging between 156.8 ± 12 nm while zeta potential ranging between − 26.1 ± 0.22 mV. They also showed high encapsulation efficiency (> 85%) and an amorphous drug’s lipid matrix state. Pharmacokinetic parameters of optimized formulation enhance oral bioavailability to 18.45%. These investigations demonstrated the superiority of NLCs for improvement of solubility as well as oral bioavailability of poorly water-soluble drugs.

Graphical Abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Beg S, Saini S, Bandopadhyay S, Katare O, Singh B. QbD-driven development and evaluation of nanostructured lipid carriers (NLCs) of Olmesartan medoxomil employing multivariate statistical techniques. Drug development and industrial pharmacy. 2018;44(3):407–20. Available from: https://doi.org/10.1080/03639045.2017.1395459

  2. Cunha S, Costa CP, Loureiro JA, Alves J, Peixoto AF, Forbes B, et al. Double optimization of rivastigmine-loaded nanostructured lipid carriers (NLC) for nose-to-brain delivery using the quality by Design (QbD) approach: formulation variables and instrumental parameters. Pharmaceutics. 2020;12(7):599. Available from: https://doi.org/10.3390/pharmaceutics12070599.

  3. Agrawal Y, Patil K, Mahajan H, Potdar M, Joshi P, Nakhate K, et al. In vitro and in vivo characterization of Entacapone-loaded nanostructured lipid carriers developed by quality-by-design approach. Drug Delivery. 2022;29(1):1112–21. Available from: https://doi.org/10.1080/10717544.2022.2058651

  4. Javed MN, Alam MS, Waziri A, Pottoo FH, Yadav AK, Hasnain MS, et al. QbD applications for the development of nanopharmaceutical products. Pharmaceutical quality by Design: Elsevier; 2019. p. 229–53. Available from: https://doi.org/10.1016/B978-0-12-815799-2.00013-7

  5. Gurumukhi VC, Bari SB. Development of ritonavir-loaded nanostructured lipid carriers employing quality by Design (QbD) as a tool: characterizations, permeability, and bioavailability studies. Drug Delivery and Translational Research. 2021:1–21. Available from: https://doi.org/10.1007/s13346-021-01083-5

  6. Gurumukhi VC, Bari SB. Quality by Design (QbD)–based fabrication of atazanavir-loaded nanostructured lipid carriers for lymph targeting: bioavailability enhancement using chylomicron flow block model and toxicity studies. Drug Delivery and Translational Research. 2022;12(5):1230–52. Available from: https://doi.org/10.1007/s13346-021-01014-4

  7. Gurumukhi VC, Bari SB. Fabrication of efavirenz loaded nano-formulation using quality by Design (QbD) based approach: exploring characterizations and in vivo safety. Journal of Drug Delivery Science and Technology. 2020;56:101545. Available from: https://doi.org/10.21203/rs.3.rs-198073/v1

  8. Mahmood A, Rapalli VK, Gorantla S, Waghule T, Singhvi G. Dermatokinetic assessment of luliconazole-loaded nanostructured lipid carriers (NLCs) for topical delivery: QbD-driven design, optimization, and in vitro and ex vivo evaluations. Drug Delivery and Translational Research. 2022;12(5):1118–35. Available from: https://doi.org/10.1007/s13346-021-00986-7

  9. Rao RR, Pisay M, Kumar S, Kulkarni S, Pandey A, Kulkarni VI, et al. Medium and large scale preparation of Nanostructured Lipid Carriers of asenapine maleate: Quality-by-design based optimization, production, characterization and performance evaluation. Journal of Drug Delivery Science and Technology. 2022:103275. Available from: https://doi.org/10.1016/j.jddst.2022.103275.

  10. Mishra V, Thakur S, Patil A, Shukla A. Quality by Design (QbD) approaches in current pharmaceutical set-up. Expert opinion on drug delivery. 2018;15(8):737–58. Available from: https://doi.org/10.1080/17425247.2018.150476

  11. Alam T, Khan S, Gaba B, Haider MF, Baboota S, Ali J. Adaptation of quality by design-based development of isradipine nanostructured–lipid carrier and its evaluation for in vitro gut permeation and in vivo solubilization fate. Journal of pharmaceutical sciences. 2018;107(11):2914–26. Available from: https://doi.org/10.1016/j.xphs.2018.07.021

  12. Rangaraj N, Pailla SR, Shah S, Prajapati S, Sampathi S. QbD aided development of ibrutinib-loaded nanostructured lipid carriers aimed for lymphatic targeting: evaluation using chylomicron flow blocking approach. Drug Delivery and Translational Research. 2020;10(5):1476–94. Available from: https://doi.org/10.1007/s13346-020-00803-7

  13. Rapalli VK, Khosa A, Singhvi G, Girdhar V, Jain R, Dubey SK. Application of QbD principles in nanocarrier-based drug delivery systems. Pharmaceutical quality by Design: Elsevier; 2019. p. 255–96. Available from: https://doi.org/10.1016/B978-0-12-815799-2.00014-9

  14. Shah B, Khunt D, Bhatt H, Misra M, Padh H. Intranasal delivery of venlafaxine loaded nanostructured lipid carrier: Risk assessment and QbD based optimization. Journal of Drug Delivery Science and Technology. 2016;33:37–50. Available from: https://doi.org/10.1016/j.jddst.2016.03.008

  15. Nabi B, Rehman S, Baboota S, Ali J. Insights on oral drug delivery of lipid nanocarriers: a win-win solution for augmenting bioavailability of antiretroviral drugs. AAPS PharmSciTech. 2019;20(2):1–11. Available from: https://doi.org/10.1208/s12249-018-1284-9

  16. Pg M, Somasundaram I. Enhancement Of Bioavilability of Perinodopril Using Lipid Based Nanocarrier Mediated Oral Drug Delivery System. Journal of Positive School Psychology. 2022;6(3):1547–52.

    Google Scholar 

  17. Khan SA, Rehman S, Nabi B, Iqubal A, Nehal N, Fahmy UA, et al. Boosting the brain delivery of Atazanavir through nanostructured lipid carrier-based approach for mitigating neuroaids. Pharmaceutics. 2020;12(11):1059. Available from: https://doi.org/10.3390/pharmaceutics12111059

  18. Hippalgaonkar K, Adelli GR, Hippalgaonkar K, Repka MA, Majumdar S. Indomethacin-loaded solid lipid nanoparticles for ocular delivery: development, characterization, and in vitro evaluation. Journal of ocular pharmacology and therapeutics. 2013;29(2):216–28. Available from: DOI: https://doi.org/10.1089/jop.2012.0069

  19. Gupta B, Poudel BK, Tran TH, Pradhan R, Cho H-J, Jeong J-H, et al. Modulation of pharmacokinetic and cytotoxicity profile of imatinib base by employing optimized nanostructured lipid carriers. Pharmaceutical research. 2015;32(9):2912--27. Available from: DOI: https://doi.org/10.1007/s11095-015-1673-7

  20. Suri R. Design of Experiments for the Development of Ophthalmic Products. Design of Experiments for Pharmaceutical Product Development: Springer; 2021. p. 117–27.

    Book  Google Scholar 

  21. Loh ZH, Samanta AK, Heng PWS. Overview of milling techniques for improving the solubility of poorly water-soluble drugs. Asian journal of pharmaceutical sciences. 2015;10(4):255–74. Available from: https://doi.org/10.1016/j.ajps.2014.12.006

  22. Gutiérrez J, González C, Maestro A, Solè I, Pey C, Nolla J. Nano-emulsions: New applications and optimization of their preparation. Curr Opin Colloid Interface Sci. 2008;13(4):245–51.

    Article  Google Scholar 

  23. Peptu C, Rotaru R, Ignat L, Cristina Humelnicu A, Harabagiu V, Anisoara Peptu C, et al. Nanotechnology approaches for pain therapy through transdermal drug delivery. Current pharmaceutical Design. 2015;21(42):6125–39. Available from: https://doi.org/10.2174/1381612821666151027152752

  24. Son G-H, Na Y-G, Huh HW, Wang M, Kim M-K, Han M-G, et al. Systemic Design and evaluation of ticagrelor-loaded nanostructured lipid carriers for enhancing bioavailability and antiplatelet activity. Pharmaceutics. 2019;11(5):222. Available from: https://doi.org/10.3390/pharmaceutics11050222

  25. Kaspera R, Kirby BJ, Sahele T, Collier AC, Kharasch ED, Unadkat JD, et al. Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo. Biochem Pharmacol. 2014;91:109–18. Available from: https://doi.org/10.1016/j.bcp.2014.06.020

  26. Sudhakar B, Krishna MC, Murthy KVR. Factorial design studies of antiretroviral drug-loaded stealth liposomal injectable: PEGylation, lyophilization and pharmacokinetic studies. Appl Nanosci [Internet]. Springer Berlin Heidelberg; 2016;6:43–60. Available from: https://doi.org/10.1007/s13204-015-0408-8

  27. Makwana V, Jain R, Patel K, Nivsarkar M, Joshi A. Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach. Int J Pharm [Internet]. Elsevier BV; 2015;495:439–46. Available from: https://doi.org/10.1016/j.ijpharm.2015.09.014

  28. Patel D, Patel B, Patel C. Spectrophotometric method for simultaneous estimation of atazanavir sulfate and ritonavir in tablet dosage form. Drug Dev Ther. 2015;6:1.

    Article  Google Scholar 

  29. Karakucuk A, Celebi N, Teksin ZS. Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach. Eur J Pharm Sci [Internet]. Elsevier BV; 2016;95:111–21. Available from: https://doi.org/10.1016/j.ejps.2016.05.010

  30. Javan F, Vatanara A, Azadmanesh K, Nabi-Meibodi M, Shakouri M. Encapsulation of ritonavir in solid lipid nanoparticles: in-vitro anti-HIV-1 activity using lentiviral particles. J Pharm Pharmacol. 2017;69:1002–9.

    Article  CAS  Google Scholar 

  31. Yogananda R, Chowdary KPR. Enhancement of solubility, dissolution rate and bioavailability of efavirenz by Cyclodextrins and Solutol HS15 - a factorial study. Int J Res Pharm Chem. 2013;3:235–9.

    CAS  Google Scholar 

  32. Patil-Gadhe A, Pokharkar V. Montelukast-loaded nanostructured lipid carriers : Part I Oral bioavailability improvement. Eur J Pharm Biopharm [Internet]. Elsevier BV; 2014;88:160–8. Available from: https://doi.org/10.1016/j.ejpb.2014.05.019

  33. Rainer HM, Ranjita S, Cornelia MK. 20 years of lipid nanoparticles (SLN & NLC): present state of development & industrial applications. Curr Drug Discov Technol. 2011;8(3):207–27. Available from: https://doi.org/10.2174/157016311796799062.

  34. Beloqui A, del Pozo-Rodríguez A, Isla A, Rodríguez-Gascón A, Solinís MÁ. Nanostructured lipid carriers as oral delivery systems for poorly soluble drugs. Journal of Drug Delivery Science and Technology. 2017;42:144–54. Available from: https://doi.org/10.1016/j.jddst.2017.06.013.

  35. Pandya P, Giram P, Bhole RP, Chang HI, Raut SY. Nanocarriers based oral lymphatic drug targeting: strategic bioavailability enhancement approaches. J Drug Delivery Sci Technol. 2021:102585. Available from: https://doi.org/10.1016/j.jddst.2021.102585.

Download references

Acknowledgements

The author, Ms. Neha Bajwa, thanks the Indian Council of Medical Research (ICMR), New Delhi, for funding her work as a senior research fellow under the ICMR-SRF scheme (F. No. 53/2019/-ECD-II dated 19/07/2019).

Author information

Authors and Affiliations

  1. Pharma Innovation Lab, Department of Pharmaceutical Sciences & Technology, Maharaja Ranjit Singh Punjab Technical University, Bathinda, 151001, Punjab, India

    Neha Bajwa, Shipra Mahal, Srishti Naryal, Preet Amol Singh & Ashish Baldi

  2. University Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, India

    Preet Amol Singh

Authors
  1. Neha Bajwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shipra Mahal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Srishti Naryal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Preet Amol Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ashish Baldi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Neha Bajwa prepared and formatted the research article and made a significant contribution to its inception and design, data collection, analysis, and interpretation. The creation of the tables and figures was assisted by Shipra Mahal and Shristi Naryal. The work was contextualized, organized, and evaluated by Preet Amol Singh. The project as well manuscript was supervised and evaluated by Dr. Ashish Baldi. The manuscript's published version has been read by all authors.

Corresponding author

Correspondence to Ashish Baldi.

Ethics declarations

Conflict of Interest

The author declare no competing interests. We certify that the submission is an original work and is not under submmited to any other journal.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bajwa, N., Mahal, S., Naryal, S. et al. Development of Novel Solid Nanostructured Lipid Carriers for Bioavailability Enhancement Using a Quality by Design Approach. AAPS PharmSciTech 23, 253 (2022). https://doi.org/10.1208/s12249-022-02386-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/s12249-022-02386-7

Keywords

Search

Navigation